H.C. Wainwright Sticks to Their Buy Rating for Vascular Biogenics (VBLT)

By Carrie Williams

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Vascular Biogenics (VBLTResearch Report) today and set a price target of $3.00. The company’s shares closed last Monday at $1.23.

According to TipRanks.com, Ramakanth ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -8.8% and a 31.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Zomedica Pharmaceuticals, ThermoGenesis Holdings, and IntelGenx Technologies.

Vascular Biogenics has an analyst consensus of Moderate Buy, with a price target consensus of $3.13, representing a 160.8% upside. In a report released yesterday, Chardan Capital also upgraded the stock to Buy with a $3.25 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $1.90 and a one-year low of $0.60. Currently, Vascular Biogenics has an average volume of 20.39K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids.